Nanocan Therapeutics Corporation
Forest Heights, MD
- UEI
- MUW6XWEVLLN3
- CAGE
- 8NZC6
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 137 National Plaza Ste 300, Forest Heights, MD 20745, USA
- Website
- nanocan.life
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Liquid immunotherapeutic fiducial eluter (life) GEL for cervical cancer - current treatment options for advanced… | National Cancer Institute | $2,996,343 | |
| Radio-immunotherapy dose-painting (raid) treatment for hormonal resistant prostate cancer - abstract prostate cancer,… | National Cancer Institute | $1,998,400 | |
| Liquid immunogenic fiducial eluter (life) for cervical cancer treatment - project summary current treatment options… | National Cancer Institute | $1,600,000 |
About Nanocan Therapeutics Corporation
Nanocan Therapeutics Corporation is a minority-owned, for-profit corporate entity specializing in advanced medical research and therapeutic technologies focused on cancer treatment. Registered in SAM.gov since July 22, 2020, the company appears to be dedicated to developing innovative immunotherapeutic approaches for treating complex cancer conditions, with a particular emphasis on developing localized treatment technologies that can improve patient outcomes and reduce treatment complexity.
The company has received multiple federal grant awards from the National Cancer Institute (NCI) for groundbreaking cancer research projects. These grants have focused on developing two primary technological innovations: the Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel for cervical cancer treatment and the Radio-Immunotherapy Dose-Painting (RAID) technology for hormonal resistant prostate cancer. The LIFE gel project aims to extend local radiotherapy's capabilities from palliative treatment to potential distant metastatic disease control, with a goal of reducing treatment time and cost while improving survival rates. The RAID technology focuses on creating an innovative radiotherapy approach for castrate-resistant prostate cancer patients, using immunogenic smart radiotherapy materials to prime the immune system and potentially achieve systemic disease control in a single treatment session. These projects involve collaborative partnerships with prestigious research institutions including Johns Hopkins University, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Northwell Health, demonstrating Nanocan's commitment to cutting-edge, collaborative medical research.
Quick answers
What is Nanocan Therapeutics Corporation's UEI?
Nanocan Therapeutics Corporation's Unique Entity ID (UEI) in SAM.gov is MUW6XWEVLLN3.
What is Nanocan Therapeutics Corporation's CAGE code?
Nanocan Therapeutics Corporation's CAGE code is 8NZC6.
What is Nanocan Therapeutics Corporation's primary NAICS code?
Nanocan Therapeutics Corporation's primary NAICS code is 541713 (Research and Development in Nanotechnology).
Where is Nanocan Therapeutics Corporation located?
Nanocan Therapeutics Corporation's physical address in SAM.gov is 137 National Plaza Ste 300, Forest Heights, MD 20745, USA.
Is Nanocan Therapeutics Corporation registered in SAM.gov?
Yes. Nanocan Therapeutics Corporation's SAM.gov registration is active through March 10, 2027.
What is Nanocan Therapeutics Corporation's most recent federal award?
Nanocan Therapeutics Corporation's most recent federal grant award is Liquid immunotherapeutic fiducial eluter (life) GEL for cervical cancer - current treatment options for advanced… (R42CA268623), from National Cancer Institute, on September 24, 2025.
On GovTribe
See Nanocan Therapeutics Corporation's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors